Coeptis and Z Squared's merger nears completion, creating a new entity with tax benefits and pending Nasdaq approval.

As of March 2026, the merger between Coeptis Therapeutics and Z Squared Inc. is nearing completion, with most regulatory and procedural steps finalized. Coeptis shareholders will receive shares in the new Z Squared entity and retain exposure to Gear Therapeutics, a spun-off biotech firm. Z Squared, a digital infrastructure company with 9,800 ASIC mining units, benefits from U.S.-approved Dogecoin ETFs and a $100 million transfer of Coeptis’s net operating losses, providing significant tax advantages. The deal awaits final Nasdaq listing approval, with trading expected on Nasdaq or OTC Markets if approved.